NEW YORK, May 31 – Motorola has decided to abandon its previously announced plans to exclusively license Molecular Staging’s rolling circle amplification technology for use in its diagnostic nucleic acid bioarrays, a spokeswoman for Molecular Staging said Thursday.
“Motorola does not have an exclusive license to the technology,” a spokeswoman for Molecular Staging said.
The spokeswoman said she did not know what prompted Motorola to cancel the agreement.
A Motorola spokeswoman declined to comment.
In December, Motorola announced that it had reached an agreement to exclusively license Molecular Staging’s technology in exchange for licensing fees and an equity investment in the privately-held company. Motorola also received an option to increase its stake in the company in the future.
It was not immediately clear whether Motorola had also cancelled its plans to invest in Molecular Staging.
RCAT is an amplification method designed to allow users to detect the presence of target molecules on a variety of formats.